Condition: Breast Cancer · Sponsor: Fudan University
This is a prospective, randomized, open-label phase III clinical study on the efficacy and safety of fluzoparib combined with adjuvant endocrine therapy versus adjuvant endocrine therapy for HR+/HER2- SNF3-subtype early breast cancer.
This description comes directly from the study's public registry record.
Zhimin Shao, MD, PhD · +86-021-64175590 · zhimingshao@yahoo.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Recruiting |
| Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangdong, Guangzhou, China | Recruiting |
| Affiliated Hospital of Nantong University | Nantong, Jiangsu, China | Recruiting |
| Northern Jiangsu People's Hospital | Yangzhou, Jiangsu, China | Recruiting |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
| Liaoning Cancer Hospital & Institute | Shenyang, Liaoning, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai First Maternity and Infant Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05891093